On the Record · Bard C R

Bard C R acquisitions, on the record

The businesses Bard C R bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
Lutonix, Inc. Word for word“In December 2011, Bard acquired Lutonix, Inc., a development stage company specializing in drug-coated balloon technology for the treatment and prevention of vascular disease.” 10-K for 2014	acquisition	December 2011	—
Rochester Medical Corporation Word for word“In November 2013, Bard acquired Rochester Medical Corporation and its line of intermittent self-catheters and male external catheters.” 10-K for 2014	acquisition	November 2013	—
Neomend, Inc. Word for word“In 2012, Bard acquired Neomend, Inc., whose Progel © surgical sealant is the only FDA-approved product available for intraoperative sealing of air leaks in connection with thoracic surgery.” 10-K for 2014	acquisition	2012	—
Medafor, Inc. Word for word“In October 2013, Bard acquired Medafor, Inc. and its Arista ® AH plant-based hemostat product line complementing Bard’s Progel © surgical sealant technology.” 10-K for 2014	acquisition	October 2013	—
Loma Vista Medical, Inc. Word for word“The total purchase consideration of $39.4 million included an up-front cash payment of $32.5 million and the fair value of contingent consideration of up to $8.0 million.” 10-K for 2014	acquisition	—	$39.4 million
early-stage technology from 3DT Holdings LLC Word for word“3DT received an up-front cash payment of $29.5 million and is eligible for a milestone payment of up to $5.0 million based upon regulatory product approval.” 10-K for 2014	acquisition	—	$29.5 million
electrophysiology division Word for word“On November 1, 2013, the company closed on the sale of certain assets and liabilities of its electrophysiology division (the “EP Sale”) to Boston Scientific Corporation (“Boston Scientific”) and received net” 10-K for 2014	divestiture	On November 1, 2013	—
Liberator Medical Holdings, Inc. Word for word“On January 21, 2016, the company acquired all of the outstanding shares of Liberator Medical Holdings, Inc. (“Liberator”), a publicly-held direct-to-consumer distributor of urological catheters, ostomy supplies, mastectomy fashions and diabetic medical supplies for approximately $181 million.” 10-K for 2015	acquisition	January 21, 2016	approximately $181 million
Embo Medical Limited Word for word“The total purchase consideration included an up-front cash payment of $21.0 million and the fair value of future contingent consideration of up to $22.5 million.” 10-K for 2015	acquisition	—	up-front cash payment of $21.0 million and the fair value of future contingent consideration of up to $22.5 million
Medicon, Inc. Word for word“The total consideration of $138.0 million, denominated in Japanese Yen, included an up-front cash payment of approximately $24.9 million at closing; the present value of future payments totaling approximately $65.8 million; settlement of an accounts receivable balance due from Medicon of $42.0 million; and the fair value of an off-market supply contract of $5.3 million.” 10-K for 2015	acquisition	—	$138.0 million
Vascular Pathways, Inc. Word for word“The total purchase consideration of $81.5 million included the fair value of future contingent consideration of up to $15 million, which is based on specific revenue-based and manufacturing-related milestones.” 10-K for 2015	acquisition	—	$81.5 million

As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year ended	Cash paid for acquisitions (net of cash acquired)
2016-12-31	$202.8 million

Deal filings since 2016

2017-12-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-07-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-05-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-04-24 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-11-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-05-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement

Read from Bard C R’s annual reports (10-K for 2016, 10-K for 2015, 10-K for 2014) and the financial data it files with the SEC, as of 2017-02-13. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.